Merck & Co.

Case Overview
52 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 04/14/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Merck & Co. |
Court: | Court: District of New Jersey |
Case Number: | Case Number: 2:25cv01208 |
Class Period: | Class Period: 02/03/2022 - 02/03/2025 |
Ticker: | Ticker: MRK |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Merck & Co. (“Merck” or the “Company”) (NYSE:MRK) securities during the period from February 3, 2022, through February 3, 2025 (“the Class Period”). Investors have until April 14, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On February 4, 2025, Merck announced that it would no longer achieve the long-forecasted $11 billion in sales of Gardasil, a vaccine developed by Merck and used in the prevention of HPV, by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Merck claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” On this news, the price of Merck shares declined by $9.05 per share, from $99.79 per share on February 3, 2025, to close at $90.74 on February 4, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose the true state of Gardasil’s demand in China; notably, that Merck lacked visibility into demand for Gardasil in China among eligible and otherwise target populations, resulting in the inflated inventory of its Chinese distributor, Zhifei.
On February 4, 2025, Merck announced that it would no longer achieve the long-forecasted $11 billion in sales of Gardasil, a vaccine developed by Merck and used in the prevention of HPV, by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Merck claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” On this news, the price of Merck shares declined by $9.05 per share, from $99.79 per share on February 3, 2025, to close at $90.74 on February 4, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose the true state of Gardasil’s demand in China; notably, that Merck lacked visibility into demand for Gardasil in China among eligible and otherwise target populations, resulting in the inflated inventory of its Chinese distributor, Zhifei.